Mithra Signs LSA for Commercialization of Myring™ in Switzerland

Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland Production of Myring™ at the Mithra CDMO facility in Belgium Agreement follows licensing deals with major international market leaders for commercialization of Myring™ Liege, Belgium, 05 December 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today […]

European Authorities Approve Advantageous Modifications to Myring™ labelling

Removal of requirement for special temperature storage for vaginal contraceptive ring Myring™ Competitive advantage in terms of reduced costs and convenience for distributors, pharmacists and patients Similar labelling to be pursued in the United States Liege, Belgium, 08 November 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces […]

Notice of Extraordinary Shareholders Meeting on 29th November 2019

Liege, Belgium, 30 October 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its intention to hold an Extraordinary General Meeting (“EGM”) on the 29 November 2019 at 2:00 PM in Flémalle 57 rue de l’Expansion (Belgium).

Mithra Signs LSA for Commercialization of Myring™ and Tibelia® in Eastern Europe

Mithra grants exclusive license to Aicore Life Sciences for commercialization of Myring™ and Tibelia® in Eastern Europe Production of Myring™ at the Mithra CDMO facility in Belgium Agreement follows licensing deals with major international market leaders for commercialization of Myring™ Liege, Belgium, 24 October 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated […]

Mithra Announces Publication of Estelle® Abstracts in Connection with the 13th Annual Meeting of the European Society of Gynecology

Liege, Belgium, 22 October 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of abstracts on Estelle® clinical results presented at the 13th Annual Meeting of the European Society of Gynecology (ESG) held from 16-19 October 2019 in Vienna, Austria.

Presentation of Estelle® Phase III results at the 13th Meeting of the European Society of Gynecology

Mithra today announces that its Phase III results for Estelle® will be presented at the 13th Annual Meeting of the European Society of Gynecology (ESG) taking place from 16-19 October 2019 in Vienna, Austria.

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

Mithra grants an exclusive license for commercialization of vaginal contraceptive ring in China The introduction of a long acting contraceptive method represents a compelling new alternative for women in China Liege, Belgium, 14 October 2019, 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into […]

Mithra Initiates Phase III Clinical Program for Donesta®

Recruitment of the first patient marking the launch of “E4 Comfort” Phase III Clinical Program for Donesta® in menopausal women with vasomotor symptoms Phase III program includes two pivotal studies aimed at enrolling a total of 2200 women aged from 40 to 65 years Liege, Belgium, 9 October 2019 – 7:30  CEST – Mithra (Euronext Brussels: […]

Mithra Provides Supplementary Details on Estelle® US Deal with Mayne

Liege, Belgium, 3 October 2019 – 7 :30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today provides supplementary details related to the US deal with Mayne Pharma for Estelle®.

Mithra Sucessfully Renegotiates Earnout Payments

Remaining payment obligations to Uteron Pharma reduced by 62% to EUR 250 million otal payment duration reduced by twelve years Substantial reduction of total debt under IFRS Significant cash flow improvement safeguarding the development of Estelle® and Donesta® Option for Mithra to pay EUR 40 million cash tranche in equity Liege, Belgium, 1 October 2019 […]